Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We are No1!
If it works out I'll send a years supply of specials NFT
Well thanks NFT's. I guess that's my hopes and dreams down the toilet.
I was looking forward to a bumper deal so I could finally wind down, perhaps open a little cafe in the country. Had it all planned out, name and logo:
-- The Dirty Samosa: As far as hygiene ratings go
Either a raise or it gets stuffed into another company at a terrible price to shareholders but keeps those NED’s filed with free stock
Jiving, I understand what you're saying but if the discussions started back in October then the importance of orphan status must have been made clear to them early on. They would have had plenty of opportunity to get the ball rolling.
They were obviously prepared for the normal EU patent submission, surely the application for orphan status is just an extension of the work already done for that.
Every extra moment of delay is an opportunity for partners to change their mind and walk away. They must surely understand that. I therefore believe that they have had every opportunity to get that submission in for March and stand by what I said.
FFX. The patent news was welcome & clearly necessary before we get into serious licensing discussions. The process of applying for orphan status appears to be a 3-5 month process depending on whether they sought a preliminary meeting prior to formal application & also whether they began in March or April or later. So if we dont get the orphan status announcement next week I dont view it as negative, but if we hear nothing by say September I would be concerned.
If they were to raise again before the lights go out in a few months now is the time to do it. Otherwise it gets too late ⏰ like others it then becomes very damaging to SP. So quick raise now might give them enough to see the end of the year. Or they see no deal coming so a flash sale to another company but very damaging to shareholders without doubt. 😕
Did Simply Wall Street send out a warning before the AVCT placing?
Even simply wall street sending out messages of warnings. Very unusual.
“
Nuformix
NFX
Share Price 7 Day 1 Year
0.00 -11.8% -26.5%
New major risk - Financial position
The company has less than a year of cash runway based on its current free cash flow trend.
Free cash flow: -UK£438k
This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk.
Currently, the following risks have been identified for the company:
Major Risks
Less than 1 year of cash runway based on free cash flow trend (-UK£438k free cash flow).
Revenue is less than US$1m.
Market cap is less than US$10m (UK£1.47m market cap, or US$1.87m).
Minor Risks
Share price has been volatile over the past 3 months (11% average weekly change).
Shareholders have been diluted in the past year (16% increase in shares outstanding).”
Well then the mms are not doing a very good manipulation job NFT!
Doesn't look like it to me, but of course these things happen in biotech shares. For example AVCT - a lot of suckers bought in there over 100p only for there to be a desperation placing at 50p & then all it does is still go down after that. Boy I would be mad to be one of those suckers, I mean why not buy now at around 40p - but no it still doesn't make sense, wait for say 10-13p & then look at it again.
Started: Transhaven, 18 Jun 2024 11:41
Last post: littlened, 18 Jun 2024 11:50
I am amazed that the fact NFX may need more shareholder cash if no patent buyers appear soon should be a surprise.NFX have no income yet
I am so glad I re-invested 5k here.....
Now I get to be stuck with everyone else that invests here :) AGAIN.....
Oh well - things can only get better! I am not complaining, just annoyed at myself.
Started: JohnnyFunerals, 18 Jun 2024 10:50
Last post: JohnnyFunerals, 18 Jun 2024 10:50
Two days and Two RNS's
Yesterday we were all pleased to read the formal confirmations that the various worldwide patents...
Too long a holder here to get carried away with excitement but welcome news all the same.
Just 24 hours later and today the RNS sees the share price fall back to on or around its 12 month low...
We so need to hear positive news on a good deal.... soon..
The only benefit lynparza that NFX managed was to make a formula that used fractionally less powder than original. Without significant resources to continue RandD in NXP004 it’s at a standstill.
It’s been a do or die scenario here for last 2 to 3 years. The incorrect track taken was by Anne who spent the cash on rat studies to achieve a poor result on NXP002. Reason being rats are poor replication of humans but cheap and easy and what they all trained doing so struggled to understand the more positive modern human tissue testing route.
This would have achieved a positive result and left money to take NXP002 further much further to a point of early license deal.
It is what it is unfortunately for investors here and any outcome now even at this price would be a positive. Clock is ticking and a merger into a new small biotech is probably what happens with current shareholders getting stock in that company but most likely at significant discount to now. IMO
Started: NFTs, 18 Jun 2024 07:42
Last post: james2k66, 18 Jun 2024 07:56
Shame though that terrible placings have ruined nfx and avct (and most aim stocks at the moment tbf)
Shame that you rail against people with negative agendas in avct (fair enough) but then come here and do the same?
Not sure what’s worse tbh.
As of March 31st £183,000 losing around £25,000 a month so another £75,000 off that now. Therefore approx 115,000 left in the pot! Or 4/5 months till the end.
Or
These words “ continue to operate until our R&D and targeted partnering activities require further resource”
The last raise was that. The last till some other company take the going concern off their hands at mates rates ensuring certain players get a seat and stock in that entity. Mmm remember those shares allotted in Oxcillio?
Started: unknownquantity, 17 Jun 2024 18:36
Last post: unknownquantity, 17 Jun 2024 18:36
Encouraging take away from the RNS today:
NXP002 Method of Use: The US PTO issued a grant of patent application 17/365,490 on 14 June 2024, covering use of the Company's proprietary drug forms in the treatment of VARIOUS DISEASES including fibrotic lung diseases.
"In terms of revenue, the fastest-growing application segment for Tranilast is in the medical field for treating fibrotic diseases such as chronic kidney disease and pulmonary fibrosis. The increasing prevalence of these conditions is driving the demand for Tranilast as an effective treatment option." (2024-2031)
Ref: https://medium.com/@brendamoreno1988/tranilast-market-research-report-its-history-and-forecast-2024-to-2031-364757c4b049
GLA, DYOR
UQ
Started: whowrotethis, 17 Jun 2024 12:08
Last post: whowrotethis, 17 Jun 2024 12:08
1. NFX have acquired patents for NXP 002 and NXP 004
2. NFX appear to be in ‘discussions’
Good news but that is it for now.
Started: olderbutwiser, 17 Jun 2024 08:16
Last post: goupplease, 17 Jun 2024 11:48
When the orphan designation is granted is that the thing that will move this
Today's news welcome but not the mover
Good to see recognition of the patents we know were signed off.
Still no word on whether they’ve submitted for Orphan designation yet.
Very encouraging. As is the language used regarding “ongoing discussions with potential development partners” (plural)
You wait for news of one patent and four come along at once.
Hope subsequent rns's follow suit.
Started: olderbutwiser, 17 Jun 2024 10:46
Last post: ForFXSake, 17 Jun 2024 10:52
Amen to that!
Kangarooos - account created 2 days ago - stop filling the thread with puerile spamming nonsense.
Last post: pjmcgra, 17 Jun 2024 09:58
WOW !
Started: goupplease, 17 Jun 2024 08:04
Last post: Soupdragon78, 17 Jun 2024 08:34
Prediction?… the world will keep spinning round.
Predictions please
Started: whowrotethis, 17 Jun 2024 07:14
Last post: ForFXSake, 17 Jun 2024 07:49
At last!
I like (and timely)
Surely not much longer to wait now ?
Dan Gooding
“The granting of these patents is very helpful and timely in progressing on-going discussions with potential development partners."
Started: goupplease, 17 Jun 2024 07:09
Last post: Drago1, 17 Jun 2024 07:10
Ready to deal
Goodnews
Last post: ForFXSake, 14 Jun 2024 07:40
It's now 80 days since the 27th March. The date tipped by some at the time as being the next opportunity for orphan status submission!
Only 10 days to go!
Started: Soupdragon78, 10 Jun 2024 15:53
Last post: ForFXSake, 13 Jun 2024 07:37
It seems from earlier posts here that there is no problem when it comes to taking time out to promote companies like Qureight over in the States. So why is it so difficult to formally announce an important EU patent grant to promote Nuformix?
Is someone afraid of investors noticing this company and driving the price up?
They've been talking probably since October last year.
"Value is only added by doing a deal, nothing else."
How many years have they been talking now? Maybe the dea'ls done and dusted but Dan can't afford the RNS to tell anyone about it
UK patent is covered under the European Patent.
Nice find SOUP, the bus Is just rolling now.
Can I ask is there a UK patent or does it not matter.
PJ
Started: Transhaven, 10 Jun 2024 12:46
Last post: chablard, 11 Jun 2024 17:58
Didn't know he was married
I was kicked for saying they needed money and lo and behold they raised money.Citygirl wants to take her head out of her proverbial and listen to various opinions instead licking Dans ring.
I agree.
One wonders why DG (if it is DG) prefers to use that to share information than using a channel open to all shareholders and potential investors
Sorry to hear they blocked you out TH. In my view user controlled groups like telegram are self defeating anyway, very little constructive ever comes out of them. Its just a power trip for those with admin rights to ban folk that don't fit their narrative.
Thats why I like LSE where posters can't even edit their own posts, let alone delete them or ban people.
Don't bother with it. Just full of Dan's mates that think that giving zero information out and ignoring questions sent to investor relations is good practice.
I was apparently being antagonistic pointing this out and got kicked.
Avoid!
“As Lynparza’s patent protection will expire in the US in 2028, there is an anticipated downshift in sales post-patent expiry”
https://www.biopharma-reporter.com/Article/2024/04/25/astrazeneca-s-lynparza-to-remain-dominant-in-parp-inhibitors-market
Started: olderbutwiser, 31 May 2024 16:15
Last post: Transhaven, 4 Jun 2024 10:54
No need for filters, I don't mind reading your negative slanted comments 4FX, sometimes they are a bit annoying, same as me on occation!
Balanced conversation and all that :)
We have a nice convo flowing on this BB so lets try and keep it that way. We can have a collective laugh at the various PnD crews that like to rev up the SP unsuccessfully :)
Most of those that have been and gone since won't have made much, Chab. Only those that didn't pay for their shares (or got them via a discounted fundraiser) will have done ok if they offloaded.
The big question is how many of the 37m club are actually left?
Spot on Chab.
"When was the last time any shareholder was rewarded here, riddle me that?"
I'll answer you that FFX.
It was when one of the company directors sold out with inside information about a certain chinese company no longer in the running.
Mind you it was years ago when the sp was ten pence or so. Ahhh been a lot of water under the bridge since then . Many a peep been and gone, which if truth be told was pretty astute of them looking at the current sp.
ATB
Unsubstantiated negativity 😂
When was the last time any shareholder was rewarded here, riddle me that?
Trombone is just another trader that can't abide opinions that don't match their own and doesn't anyone else to hear them either
Started: Willowman19, 31 May 2024 17:51
Last post: Willowman19, 31 May 2024 17:51
Had a reply from Tim Metcalf last week.
I said about expecting a bit of showboating from Dr Dan, Tim replied that people are working hard to progress NFX. Lots going on behind the scenes with nothing ATM that can be made public.
When they can make information public, they will.
Started: olderbutwiser, 31 May 2024 17:13
Last post: olderbutwiser, 31 May 2024 17:13
Companies can apply for orphan status directly themselves or use specialist submission companies who are versed in the submission requirements and application process.
This was Dan's verbatim response to a specific question:
Q. How long is getting orphan drug status likely to take?
A. 3 months if we can start now.
So there is no room in that answer for a two month pre-submission delay.
I think we just have to wait until the second or the fourth week of June to see what transpires and if anything has been submitted.
ATB and have a good weekend all.
Started: olderbutwiser, 31 May 2024 15:54
Last post: olderbutwiser, 31 May 2024 15:54
Yes I agree Soup - there is the option that a company can have a pre-submission meeting a couple of months before submitting 'If a sponsor feels they could benefit from a preliminary discussion before the submission of an orphan drug'.
But the guidance does not say that they should have a pre-submission meeting it is optional.
Last post: Soupdragon78, 31 May 2024 14:35
FX, yes he apparently said they would go for orphan status, he didn't say when they would though.
This isn't like when applied for your bus pass, you have to pull a lot of information together and get it right. I would envisage they need to employ someone to do so and it would take a period of time.
As I've mentioned before, the guidance says that a company should have a pre-submission meeting at least two months before submitting.
So even if they started the process in early March, they may only be getting to the point where they are in a good position to apply.
Thought this was interesting especially the latter part where the new method has to be superior to the existing.
One of the key differences between the orphan designation process in the EU and US is that, in the latter the emphasis is on demonstrating the scientific rationale and disease prevalence, whilst in the EU there are two additional requirements: i) that the condition is life-threatening or seriously debilitating, and ii) that there is currently either no satisfactory method (of diagnosis, prevention or treatment) or that the new product will be of significant benefit over the existing method. Any product with a MA in any EU country would be considered to be a “satisfactory” method and, even where a product is not authorised, if it is widely used it may be considered to be satisfactory. In such a case, the applicant needs to provide a solid argument as to why the new method is expected to be superior.
Sounds like another excuse for nothing happening again.
Correct me if I'm wrong but I thought the words translated from the Telgram moot were something along the lines of : 'our competition have akl applied for orphan status so we must have it if want to stand any chance of a deal'?
Is that not the case now?
If not then what exactly was the fundraiser money for?
I'll go back to my point about Dan's telegram comment, from what was reported he apparently only said they were thinking about orphan designation application and leaning towards EU side.
I would expect they would need someone to pull together the documentation on their behalf and submit. So I doubt the application went in straight away, if at all yet.
FX you need to read Olders posts on orphans. Notice of approval does not happen from application. Notice if approved is 30 days from review meeting or 60 days if questions. Review meetings happen once a month around 21st/22nd, applications have to be in to meet the prep time to be submitted to the meeting. There was an IPF product reviewed at the meeting on 21/22nd May so the earliest we will hear is 22nd June. My own view is NXP002 has had a very thorough preclinical with substantive results so I would be surprised if there were questions. IPF is clearly an orphan case and Tranilast is already on the orphan database for another use. We can only hope it was NXP002 that was reviewed in May bit of a coincidence so must be a better chance than 50/50
Started: olderbutwiser, 28 May 2024 09:10
Last post: Transhaven, 30 May 2024 23:31
Think the sentiment was "hopefully something meaningful". Hope was dashed on the rocks of company and Dan silence.
that sentence made sense to my stoned mind 😘
FFS Totally agree rediculas
It's a sorry state when less than £20k of trades in one day can be misconstrued as 'something meaningful'
As yet no sign of the Earl & his wisdom?
Hopefully something meaningful is happening and it is not just PIs throwing in money because the SP dipped below average.
Started: pjmcgra, 24 May 2024 16:50
Last post: chablard, 25 May 2024 10:54
Lol
Soup, agreed , nice to see blue here today.